Cadence Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Cadence Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-52,820	Closed	-$666K	–	682
2017 Q4	$666K	Buy	52,820 +3,824	+8%	+$48.3K	0.04%	444
2017 Q3	$634K	Buy	48,996 +22,986	+88%	+$303K	0.04%	457
2017 Q2	$386K	Buy	+26,010	New	+$362K	0.03%	564
2014 Q1	–	Sell	-86,740	Closed	-$1.05M	–	624
2013 Q4	$1.05M	Buy	86,740 +25,700	+42%	+$307K	0.04%	427
2013 Q3	$745K	Sell	61,040 -12,440	-17%	-$174K	0.03%	488
2013 Q2	$971K	Buy	+73,480	New	+$1.02M	0.05%	313

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Cadence Capital Management's LFCR Position: Q1 2018 in Review

Cadence Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2018, closing a stake of 52,820 shares — an estimated $666K sold.

Cadence Capital Management first reported a position in LFCR in Q2 2013 and held it in 6 quarters. The position peaked at $1.05M in Q4 2013. 89 funds tracked by Wall St. Rank hold LFCR as of Q1 2018.

Cadence Capital Management reported no remaining Lifecore Biomedical position as of Q1 2018 after selling out during the quarter.
Cadence Capital Management sold 52,820 Lifecore Biomedical shares in Q1 2018, an estimated $666K.
Cadence Capital Management first reported a position in Lifecore Biomedical in Q2 2013 and held it in 6 quarters.
Cadence Capital Management's Lifecore Biomedical position peaked at $1.05M in Q4 2013.
89 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2018.

Based on Cadence Capital Management's 13F filing for Q1 2018, filed 14 May 2018.